Zoledronic acid for treament of prostate cancer

Bookmark and Share
Published: 25 Jun 2009
Views: 16172
Dr. Thomas W. Leonard, Chief Scientific Officer, Merrion Pharmaceuticals
Results of Phase II study comparing Orazol (zoledronic acid in oral form) to Zometa (zoledronic acid IV) injections in treatment of prostate cancer, as presented at the ASCO Meeting, 2009. Further comment from Chief Development Officer Dr John Fox.